On May 22, 2023, Lyell Immunopharma Inc. (NASDAQ: LYEL) opened at $2.76, higher 4.71% from the last session. During the day, the shares moved up to $2.96 and dropped to $2.76 before settling in for the closing price of $2.76. Price fluctuations for LYEL have ranged from $1.77 to $8.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 28.80% at the time writing. With a float of $210.08 million, this company’s outstanding shares have now reached $249.59 million.
The firm has a total of 274 workers. Let’s measure their productivity. In terms of profitability, gross margin is +80.55, operating margin of -226.51, and the pretax margin is -216.24.
Lyell Immunopharma Inc. (LYEL) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lyell Immunopharma Inc. is 3.10%, while institutional ownership is 66.00%. The most recent insider transaction that took place on Sep 23, was worth 71,041. In this transaction Director of this company sold 11,100 shares at a rate of $6.40, taking the stock ownership to the 988,900 shares.
Lyell Immunopharma Inc. (LYEL) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 3/30/2023, the company posted -$0.23 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.28) by $0.05. This company achieved a net margin of -216.24 while generating a return on equity of -20.77. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.80% per share during the next fiscal year.
Lyell Immunopharma Inc. (NASDAQ: LYEL) Trading Performance Indicators
Check out the current performance indicators for Lyell Immunopharma Inc. (LYEL). In the past quarter, the stock posted a quick ratio of 20.30. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.73, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.37 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc. (LYEL)
Analysing the last 5-days average volume posted by the [Lyell Immunopharma Inc., LYEL], we can find that recorded value of 0.83 million was lower than the volume posted last year of 1.0 million. As of the previous 9 days, the stock’s Stochastic %D was 61.94%. Additionally, its Average True Range was 0.25.
During the past 100 days, Lyell Immunopharma Inc.’s (LYEL) raw stochastic average was set at 60.87%, which indicates a significant decrease from 84.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.55% in the past 14 days, which was higher than the 94.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.37, while its 200-day Moving Average is $4.27. Now, the first resistance to watch is $2.98. This is followed by the second major resistance level at $3.07. The third major resistance level sits at $3.18. If the price goes on to break the first support level at $2.78, it is likely to go to the next support level at $2.67. Should the price break the second support level, the third support level stands at $2.58.
Lyell Immunopharma Inc. (NASDAQ: LYEL) Key Stats
There are currently 249,609K shares outstanding in the company with a market cap of 658.63 million. Presently, the company’s annual sales total 84,680 K according to its annual income of -183,120 K. Last quarter, the company’s sales amounted to 70 K and its income totaled -66,960 K.
